1	Efficient	Efficient	B-NP	JJ	O	2	NMOD	-1
2	inhibition	inhibition	I-NP	NN	O	0	ROOT	18	inhibition
3	of	of	B-PP	IN	O	2	NMOD	-1
4	ovarian	ovarian	B-NP	JJ	O	6	NMOD	-1
5	cancer	cancer	I-NP	NN	O	6	NMOD	-1
6	growth	growth	I-NP	NN	O	9	NMOD	4	growth
7	and	and	O	CC	O	9	NMOD	-1
8	prolonged	prolonged	B-NP	JJ	O	9	NMOD	0
9	survival	survival	I-NP	NN	O	3	PMOD	5	survival
10	by	by	B-PP	IN	O	2	NMOD	-1
11	transfection	transfection	B-NP	NN	O	10	PMOD	19	transfection
12	with	with	B-PP	IN	O	11	NMOD	-1
13	a	a	B-NP	DT	O	16	NMOD	-1
14	novel	novel	I-NP	JJ	B-DNA	16	NMOD	-1
15	pro-apoptotic	pro-apoptotic	I-NP	JJ	I-DNA	16	NMOD	-1
16	gene	gene	I-NP	NN	I-DNA	18	NMOD	-1
17	,	,	O	,	O	18	P	-1
18	hPNAS-4	hPNAS-4	B-NP	NN	B-DNA	12	PMOD	-1
19	,	,	O	,	O	2	P	-1
20	in	in	B-PP	IN	O	2	NMOD	-1
21	a	a	B-NP	DT	O	23	NMOD	-1
22	mouse	mouse	I-NP	NN	O	23	NMOD	-1
23	model	model	I-NP	NN	O	20	PMOD	-1
24	.	.	O	.	O	2	P	-1

1	In	In	B-ADVP	FW	O	2	AMOD	-1
2	vivo	vivo	I-ADVP	FW	O	6	NMOD	-1
3	and	and	O	CC	O	6	NMOD	-1
4	in	in	B-NP	FW	O	5	AMOD	-1
5	vitro	vitro	I-NP	FW	O	6	NMOD	-1
6	results	result	I-NP	NNS	O	0	ROOT	0
7	.	.	O	.	O	6	P	-1

1	OBJECTIVE	OBJECTIVE	B-NP	NN	O	4	VMOD	-1
2	:	:	O	:	O	4	P	-1
3	We	We	B-NP	PRP	O	4	SUB	-1
4	transfected	transfecte	B-VP	VBD	O	0	ROOT	19	transfected
5	ovarian	ovarian	B-NP	JJ	B-cell_type	7	NMOD	-1
6	cancer	cancer	I-NP	NN	I-cell_type	7	NMOD	-1
7	cells	cell	I-NP	NNS	I-cell_type	4	OBJ	-1
8	and	and	O	CC	O	4	VMOD	-1
9	administered	administer	B-VP	VBN	O	4	VMOD	19	administered
10	recombinant	recombinant	B-NP	JJ	B-DNA	11	NMOD	-1
11	plasmid	plasmid	I-NP	NN	I-DNA	9	OBJ	-1
12	encoding	encode	B-VP	VBG	O	11	NMOD	-1
13	hPNAS-4	hPNAS-4	B-NP	NN	B-protein	12	OBJ	-1
14	to	to	B-PP	TO	O	9	VMOD	-1
15	nude	nude	B-NP	JJ	O	16	NMOD	-1
16	mice	mouse	I-NP	NNS	O	14	PMOD	-1
17	bearing	bear	B-VP	VBG	O	16	NMOD	-1
18	ovarian	ovarian	B-NP	JJ	O	19	NMOD	-1
19	cancer	cancer	I-NP	NN	O	17	OBJ	-1
20	,	,	O	,	O	4	P	-1
21	aiming	aim	B-VP	VBG	O	4	VMOD	-1
22	to	to	I-VP	TO	O	23	VMOD	-1
23	evaluate	evaluate	I-VP	VB	O	21	VMOD	-1
24	the	the	B-NP	DT	O	25	NMOD	-1
25	effect	effect	I-NP	NN	O	23	OBJ	16	effect
26	of	of	B-PP	IN	O	25	NMOD	-1
27	hPNAS-4	hPNAS-4	B-NP	NN	O	26	PMOD	-1
28	against	against	B-PP	IN	O	25	NMOD	0
29	ovarian	ovarian	B-NP	JJ	O	30	NMOD	-1
30	cancer	cancer	I-NP	NN	O	28	PMOD	-1
31	in	in	B-ADVP	FW	O	23	VMOD	-1
32	vitro	vitro	I-ADVP	FW	O	31	AMOD	-1
33	and	and	O	CC	O	31	AMOD	-1
34	in	in	B-ADVP	FW	O	31	AMOD	-1
35	vivo	vivo	I-ADVP	FW	O	34	AMOD	-1
36	.	.	O	.	O	4	P	-1

1	METHODS	METHODS	B-NP	NNS	O	0	ROOT	-1
2	:	:	O	:	O	1	P	-1
3	Ovarian	Ovarian	B-NP	JJ	B-cell_type	6	NMOD	-1
4	cancer	cancer	I-NP	NN	I-cell_type	6	NMOD	-1
5	SKOV3	SKOV3	I-NP	NN	I-cell_type	6	NMOD	-1
6	cells	cell	I-NP	NNS	I-cell_type	7	SUB	-1
7	were	be	B-VP	VBD	O	15	VMOD	-1
8	transfected	transfecte	I-VP	VBN	O	7	VC	19	transfected
9	with	with	B-PP	IN	O	8	VMOD	-1
10	hPNAS-4-plasmid	hPNAS-4-plasmid	B-NP	NN	B-DNA	9	PMOD	-1
11	,	,	O	,	O	15	P	-1
12	and	and	O	CC	O	14	NMOD	-1
13	cell	cell	B-NP	NN	O	14	NMOD	-1
14	proliferation	proliferation	I-NP	NN	O	15	SUB	1	proliferation
15	was	be	B-VP	VBD	O	22	VMOD	-1
16	evaluated	evaluate	I-VP	VBN	O	15	VC	-1
17	by	by	B-PP	IN	O	16	VMOD	-1
18	MTT	MTT	B-NP	NN	O	19	NMOD	-1
19	assay	assay	I-NP	NN	O	17	PMOD	-1
20	;	;	O	:	O	22	P	-1
21	apoptosis	apoptosis	B-NP	NN	O	22	SUB	5	apoptosis
22	was	be	B-VP	VBD	O	1	NMOD	-1
23	examined	examine	I-VP	VBN	O	22	VC	-1
24	by	by	B-PP	IN	O	23	VMOD	-1
25	DNA	DNA	B-NP	NN	O	26	NMOD	-1
26	ladder	ladder	I-NP	NN	O	32	NMOD	-1
27	,	,	O	,	O	32	P	-1
28	Hoechst33258	Hoechst33258	B-NP	NN	O	29	NMOD	-1
29	staining	staining	I-NP	NN	O	32	NMOD	0
30	and	and	O	CC	O	32	NMOD	-1
31	flow-cytometric	flow-cytometric	B-NP	JJ	O	32	NMOD	-1
32	assays	assay	I-NP	NNS	O	24	PMOD	-1
33	.	.	O	.	O	1	P	-1

1	Nude	Nude	B-NP	NN	O	2	NMOD	-1
2	mice	mouse	I-NP	NNS	O	6	SUB	-1
3	bearing	bear	B-VP	VBG	O	2	NMOD	-1
4	ovarian	ovarian	B-NP	JJ	O	5	NMOD	-1
5	cancers	cancer	I-NP	NNS	O	3	OBJ	-1
6	were	be	B-VP	VBD	O	0	ROOT	-1
7	treated	treat	I-VP	VBN	O	6	VC	19	treated
8	with	with	B-PP	IN	O	7	VMOD	-1
9	hPNAS-4-p/liposome	hPNAS-4-p/liposome	B-NP	NN	O	8	PMOD	-1
10	.	.	O	.	O	6	P	-1

1	Tumor	Tumor	B-NP	NN	O	2	NMOD	-1
2	growth	growth	I-NP	NN	O	3	SUB	4	growth
3	was	be	B-VP	VBD	O	7	VMOD	-1
4	determined	determine	I-VP	VBN	O	3	VC	-1
5	and	and	O	CC	O	7	VMOD	-1
6	survival	survival	B-NP	NN	O	7	SUB	0
7	was	be	B-VP	VBD	O	0	ROOT	-1
8	recorded	record	I-VP	VBN	O	7	VC	-1
9	.	.	O	.	O	7	P	-1

1	TUNEL	TUNEL	B-NP	NN	O	2	NMOD	-1
2	assay	assay	I-NP	NN	O	5	NMOD	-1
3	and	and	O	CC	O	5	NMOD	-1
4	microvessel	microvessel	B-NP	NN	O	5	NMOD	-1
5	density	density	I-NP	NN	O	6	SUB	-1
6	was	be	B-VP	VBD	O	0	ROOT	-1
7	assessed	assess	I-VP	VBN	O	6	VC	-1
8	to	to	I-VP	TO	O	9	VMOD	-1
9	evaluate	evaluate	I-VP	VB	O	7	VMOD	-1
10	apoptosis	apoptosis	B-NP	NN	O	12	NMOD	0
11	and	and	I-NP	CC	O	12	NMOD	-1
12	angiogenesis	angiogenesis	I-NP	NN	O	9	OBJ	3	angiogenesis
13	.	.	O	.	O	6	P	-1

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT	0
2	:	:	O	:	O	1	P	-1
3	Both	Both	O	CC	O	4	NMOD	-1
4	inhibition	inhibition	B-NP	NN	O	13	NMOD	18	inhibition
5	of	of	B-PP	IN	O	4	NMOD	-1
6	proliferation	proliferation	B-NP	NN	O	5	PMOD	1	proliferation
7	(	(	O	(	O	11	DEP	-1
8	p	p	B-NP	NN	O	10	SUB	-1
9	<	<	O	SYM	O	10	VMOD	-1
10	0.05	0.05	B-NP	CD	O	11	DEP	-1
11	)	)	O	)	O	4	NMOD	-1
12	and	and	O	CC	O	13	NMOD	-1
13	induction	induction	B-NP	NN	O	21	SUB	17	induction
14	of	of	B-PP	IN	O	13	NMOD	-1
15	apoptosis	apoptosis	B-NP	NN	O	14	PMOD	5	apoptosis
16	(	(	O	(	O	20	DEP	-1
17	p	p	B-NP	NN	O	20	DEP	-1
18	<	<	B-NP	SYM	O	17	NMOD	-1
19	0.05	0.05	I-NP	CD	O	18	AMOD	-1
20	)	)	O	)	O	13	NMOD	-1
21	were	be	B-VP	VBD	O	1	NMOD	-1
22	observed	observe	I-VP	VBN	O	21	VC	0
23	in	in	B-PP	IN	O	22	VMOD	-1
24	SKOV3	SKOV3	B-NP	NN	B-cell_line	25	NMOD	-1
25	cells	cell	I-NP	NNS	I-cell_line	23	PMOD	-1
26	transfected	transfecte	B-VP	VBN	O	25	NMOD	19	transfected
27	with	with	B-PP	IN	O	26	VMOD	-1
28	hPNAS-4-p	hPNAS-4-p	B-NP	NN	O	27	PMOD	-1
29	in	in	B-ADVP	FW	O	26	VMOD	-1
30	vitro	vitro	I-ADVP	FW	O	29	AMOD	-1
31	.	.	O	.	O	1	P	-1

1	In	In	B-PP	IN	O	11	VMOD	-1
2	hPNAS-4-p-treated	hPNAS-4-p-treated	B-NP	JJ	B-cell_line	4	NMOD	19	treated
3	tumor	tumor	I-NP	NN	I-cell_line	4	NMOD	-1
4	cells	cell	I-NP	NNS	I-cell_line	1	PMOD	-1
5	in	in	B-ADVP	FW	O	6	AMOD	-1
6	vivo	vivo	I-ADVP	FW	O	4	NMOD	-1
7	,	,	O	,	O	11	P	-1
8	tumor	tumor	B-NP	NN	O	9	NMOD	-1
9	growth	growth	I-NP	NN	O	11	SUB	4	growth
10	significantly	significantly	B-ADVP	RB	O	11	VMOD	-1
11	decreased	decrease	B-VP	VBD	O	0	ROOT	18	decreased
12	,	,	O	,	O	11	P	-1
13	while	while	B-SBAR	IN	O	11	VMOD	-1
14	the	the	B-NP	DT	O	16	NMOD	-1
15	survival	survival	I-NP	NN	O	16	NMOD	5	survival
16	time	time	I-NP	NN	O	20	SUB	-1
17	of	of	B-PP	IN	O	16	NMOD	-1
18	tumor-bearing	tumor-bearing	B-NP	JJ	O	19	NMOD	-1
19	mice	mouse	I-NP	NNS	O	17	PMOD	-1
20	was	be	B-VP	VBD	O	13	SBAR	-1
21	prolonged	prolong	I-VP	VBN	O	20	VC	17	prolonged
22	compared	compare	B-PP	VBN	O	21	VMOD	-1
23	with	with	B-PP	IN	O	22	PMOD	-1
24	control	control	B-NP	JJ	O	25	NMOD	0
25	groups	group	I-NP	NNS	O	23	PMOD	-1
26	(	(	O	(	O	30	DEP	-1
27	p	p	B-NP	NN	O	30	DEP	-1
28	<	<	O	SYM	O	27	NMOD	-1
29	0.05	0.05	B-NP	CD	O	28	AMOD	-1
30	)	)	O	)	O	21	VMOD	-1
31	.	.	O	.	O	11	P	-1

1	Increased	Increase	B-NP	VBN	O	2	NMOD	17	Increased
2	apoptosis	apoptosis	I-NP	NN	O	8	NMOD	5	apoptosis
3	of	of	B-PP	IN	O	2	NMOD	-1
4	tumor	tumor	B-NP	NN	B-cell_type	5	NMOD	-1
5	cells	cell	I-NP	NNS	I-cell_type	3	PMOD	-1
6	and	and	O	CC	O	8	NMOD	-1
7	decreased	decrease	B-VP	VBD	O	8	NMOD	18	decreased
8	angiogenesis	angiogenesis	B-NP	NN	O	12	SUB	3	angiogenesis
9	in	in	B-PP	IN	O	8	NMOD	-1
10	tumor	tumor	B-NP	NN	O	11	NMOD	-1
11	tissue	tissue	I-NP	NN	O	9	PMOD	-1
12	were	be	B-VP	VBD	O	0	ROOT	-1
13	also	also	I-VP	RB	O	12	VMOD	-1
14	observed	observe	I-VP	VBN	O	12	VC	0
15	.	.	O	.	O	12	P	-1

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT	-1
2	:	:	O	:	O	1	P	-1
3	Our	Our	B-NP	PRP$	O	5	NMOD	-1
4	promising	promising	I-NP	JJ	O	5	NMOD	-1
5	results	result	I-NP	NNS	O	1	OBJ	0
6	on	on	B-PP	IN	O	5	NMOD	-1
7	the	the	B-NP	DT	O	10	NMOD	-1
8	potential	potential	I-NP	JJ	O	9	AMOD	0
9	antitumor	antitumor	I-NP	JJ	O	10	NMOD	-1
10	effects	effect	I-NP	NNS	O	21	SUB	18	effects
11	of	of	B-PP	IN	O	10	NMOD	-1
12	hPNAS-4	hPNAS-4	B-NP	NN	O	11	PMOD	-1
13	on	on	B-PP	IN	O	10	NMOD	-1
14	ovarian	ovarian	B-NP	JJ	O	15	NMOD	-1
15	cancer	cancer	I-NP	NN	O	13	PMOD	-1
16	in	in	B-ADVP	FW	O	15	NMOD	-1
17	vitro	vitro	I-ADVP	FW	O	16	AMOD	-1
18	and	and	O	CC	O	21	VMOD	-1
19	in	in	B-ADVP	FW	O	21	VMOD	-1
20	vivo	vivo	I-ADVP	FW	O	19	AMOD	-1
21	may	may	B-VP	MD	O	6	SBAR	-1
22	be	be	I-VP	VB	O	21	VC	-1
23	explained	explain	I-VP	VBN	O	22	VC	-1
24	,	,	O	,	O	23	P	-1
25	in	in	B-PP	IN	O	23	VMOD	-1
26	part	part	B-NP	NN	O	25	PMOD	-1
27	,	,	O	,	O	23	P	-1
28	by	by	B-PP	IN	O	23	VMOD	-1
29	the	the	B-NP	DT	O	30	NMOD	-1
30	induction	induction	I-NP	NN	O	34	NMOD	17	induction
31	of	of	B-PP	IN	O	30	NMOD	-1
32	apoptosis	apoptosis	B-NP	NN	O	31	PMOD	5	apoptosis
33	and	and	I-NP	CC	O	34	NMOD	-1
34	inhibition	inhibition	I-NP	NN	O	28	PMOD	18	inhibition
35	of	of	B-PP	IN	O	34	NMOD	-1
36	angiogenesis	angiogenesis	B-NP	NN	O	35	PMOD	3	angiogenesis
37	.	.	O	.	O	1	P	-1

1	Consequently	Consequently	B-ADVP	RB	O	4	VMOD	-1
2	,	,	O	,	O	4	P	-1
3	hPNAS-4	hPNAS-4	B-NP	NN	B-protein	4	SUB	-1
4	has	have	B-VP	VBZ	O	0	ROOT	-1
5	potential	potential	B-NP	NN	O	4	OBJ	0
6	as	as	B-PP	IN	O	4	VMOD	-1
7	a	a	B-NP	DT	O	10	NMOD	-1
8	new	new	I-NP	JJ	O	10	NMOD	-1
9	gene	gene	I-NP	NN	O	10	NMOD	-1
10	therapy	therapy	I-NP	NN	O	6	PMOD	0
11	for	for	B-PP	IN	O	10	NMOD	-1
12	human	human	B-NP	JJ	O	14	NMOD	-1
13	ovarian	ovarian	I-NP	JJ	O	14	NMOD	-1
14	cancer	cancer	I-NP	NN	O	11	PMOD	-1
15	.	.	O	.	O	4	P	-1

